ArticleMetabolomics : Official journal of the Metabolomic Society2026
Integrated serum metabolomics and lipidomics for identifying metabolic changes in rheumatoid arthritis.
Article in Metabolomics : Official journal of the Metabolomic Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundRheumatoid arthritis (RA) is a chronic autoimmune disorder with complex pathogenesis, and conventional biomarkers often fail to capture disease-associated metabolic changes. A more comprehensive understanding of the metabolic alterations in RA may provide deeper insights into disease mechanisms.
objectiveThis study aimed to identify serum metabolic changes associated with RA using non-targeted metabolomics and lipidomics, and to explore the potential impact of these metabolic alterations on RA pathophysiology.
methodsA case-control study was conducted using baseline data from the Inflammatory Immune Disease Cohort at the First Affiliated Hospital of Anhui Medical University (October 2021 to June 2023). A total of 91 RA patients and 125 healthy controls were included. Serum samples were analyzed by non-targeted liquid chromatography-mass spectrometry (LC-MS). Differential metabolites were identified using orthogonal partial least squares discriminant analysis (OPLS-DA), followed by filtration with Student's t-test (P < 0.05). Logistic regression was applied to identify potential metabolic alterations for further investigation. Pathway enrichment analysis identified significant metabolic pathways associated with RA.
resultsThe median age of both groups was 50.0 years, with no significant demographic differences (P > 0.05). Metabolomics and lipidomics identified 41 differential metabolites, including 16 small molecules and 25 lipids. Pathway analysis revealed disturbances in the urea cycle, sphingolipid metabolism, arginine and proline metabolism, and glycine and serine metabolism. These findings suggest systemic metabolic alterations in RA and provide new insights into the disease's metabolic profile.
conclusionsThe study identified significant metabolic alterations in RA, contributing to a better understanding of the disease's pathophysiology. These findings highlight the importance of metabolic reprogramming in RA and offer directions for further investigation into metabolic pathways involved in disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.